8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The SecuritiesExchange Act of 1934

Date of Report (Date of earliest event reported):

December 28, 2022

IMMUNIC, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (332) 255-9818

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ¨ No ¨

Item 1.01. Entry into a Material Definitive Agreement.

On December 28, 2022, Immunic, Inc. (the “Company”) and Dr. Duane Nash entered into Addendum Number 4 to the Employment Agreement dated April 17, 2020 (the “Addendum”), to extend the term of Dr. Nash’s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2023.

In connection with theAddendum, the Company increased Dr. Nash’s monthly base salary to $30,250 from $29,358.

The Addendum is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADDENDUM NO. FOUR TO EMPLOYMENTAGREEMENT

This Addendum Number Four (this “Addendum”) to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021 and March 15, 2022 (the “Employment Agreement”) that was entered into by and between IMMUNIC,INC., a Delaware corporation (the “Company”), and DUANE NASH (the “Executive”), is entered into as of December 28, 2022. Defined terms used, but not defined, herein shall have the meaning set forth in the Employment Agreement.

WHEREAS, the Executive agreed to serve in the capacity of Executive Chairman of the Board of Directors of the Company (“Board”), pursuant to the terms of the Employment Agreement, until December 31, 2022 or such later date as shall be mutually agreed to in writing by the Executive and the Company; and

WHEREAS, the Executive and the Company have agreed to extend the term of the Executive’s service as the Executive Chairman of the Board until December 31, 2023 subject to the terms of the Employment Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and for other valuable consideration, the Company and the Executive hereby agree as follows:

1.       Term of Employment. The Company and the Executive hereby agree to extend the Term of Employment from December 31, 2022 to December 31, 2023 with a Base Salary of $30,250 per month (which includes the cash retainer payable for serving on the Company’s Board or for acting as the Chairman of the Board). All other terms of the Employment Agreement shall remain the same and Section 12 (Miscellaneous) of the Employment Agreement is deemed incorporated herein to this Addendum.

IN WITNESS WHEREOF, the parties hereto have caused this Addendum to be executed as of the 28^th^ day of December 2022.